What is the proper protocol for gentamicin intravesical irrigation?

Gentamicin Bladder Irrigation Protocol

For recurrent urinary tract infections (rUTIs) in patients with neurogenic bladder or complex urological conditions performing clean intermittent catheterization (CIC), intravesical gentamicin is administered as 80 mg gentamicin in 20 mL normal saline, instilled during the final catheterization of the day and retained overnight, given once daily on alternating days for prophylaxis. 1, 2, 3

Dosing Protocols

Treatment Regimen (Acute UTI)

• Dose: 8 mg gentamicin in 20 mL 0.9% NaCl (for smaller bladder capacity) OR 20 mg gentamicin in 50 mL 0.9% NaCl (for larger bladder capacity) 2
• Frequency: Twice daily
• Duration: 7 days
• Dwell time: 60 minutes 1
• Success rate: 86% for suppressing acute UTI 2

Prophylaxis Regimen (Preventing rUTIs)

• Dose: 80 mg gentamicin in 20 mL 0.9% NaCl (most common protocol) 1, 3
  • Alternative: 14 mg in 30 mL saline 4
  • Alternative: 30-60 mL of 0.48 mg/mL solution 1
• Frequency: Once daily, every other day
• Dwell time: Overnight (instilled during final catheterization of the day) 3
• Duration: Median 252 days (range varies by patient response) 2

Intraoperative Use (Kidney Transplant)

• Dose: 160 mg gentamicin in 250 mL normal saline 5
• Timing: During ureteroneocystostomy
• Single dose only
• Note: Evidence shows limited efficacy (10.2% absolute risk reduction, not statistically significant) 5, 6

Efficacy Outcomes

Prophylaxis reduces rUTI frequency by 83-90% across multiple studies 3:

• Subjective UTI rate: median 6.5 pre-treatment vs 0 during treatment per 12-month-equivalent (p<0.00001) 1
• Objective UTI rate: median 5.5 vs 0 per 12-month-equivalent (p<0.00001) 1
• 58% of patients on prophylaxis had zero breakthrough UTIs 2
• Emergency department visits for UTI: median 1 vs 0 per 12-month-equivalent (p=0.005) 1
• Multidrug-resistant UTI prevalence: 70% vs 23% (p=0.00002) 1

Patient-Specific Considerations

Female patients derive greater benefit than males:

• Females: 50% baseline UTI risk reduced to 30.8% (NNT=5) 5
• Males: 17.1% reduced to 11.1% (NNT=17) 5

Living donor recipients show better response (NNT=7) compared to deceased donor recipients (NNT=23) 5

Safety Profile

Intravesical gentamicin demonstrates excellent safety with minimal systemic absorption 2, 4, 7:

• No detectable serum gentamicin levels in the vast majority of patients (all levels <0.4 mg/dL) 4, 7
• No documented ototoxicity or nephrotoxicity attributable to intravesical administration 2, 4
• Overall safety rate: 94.2% 3

Adverse Events

• Mild complications: 5.8-21.7% (primarily diarrhea, fungal infections—all Clavien-Dindo Grade I) 1, 3
• No serious adverse events reported across studies 3
• Gentamicin resistance emergence: 4.16% (1/24 patients) 2

Monitoring Requirements

Low-risk patients (normal renal function, no vesicoureteral reflux, no severe bladder inflammation):

• No intensive laboratory monitoring required 4
• Baseline serum creatinine recommended

High-risk patients (chronic renal insufficiency, vesicoureteral reflux, severe bladder inflammation):

• Baseline and periodic serum creatinine 4
• Random gentamicin levels if clinically indicated 4
• Consider audiology testing for prolonged use (>6 months) 2

Contraindications and Cautions

Increased absorption risk occurs with:

• Severe bladder inflammation (43% absorption in rat models with fulgurated bladders) 7
• Active upper urinary tract infection 4
• High-grade vesicoureteral reflux with elevated storage pressures (>40 cmH2O) 7

Avoid in:

• Known gentamicin hypersensitivity
• Active pyelonephritis (systemic therapy required)

Administration Technique

1. Preparation: Use sterile technique; solution stable for 2 months at room temperature without special storage 7
2. Instillation route: Via clean intermittent catheterization, suprapubic catheter, or indwelling catheter 2
3. Timing: For prophylaxis, instill during final catheterization of the day 3
4. Dwell time: 60 minutes minimum for treatment; overnight for prophylaxis 1, 3
5. Patient positioning: No specific positioning required

Clinical Pitfalls

• Do not use for upper tract infections: Intravesical gentamicin is ineffective for pyelonephritis; systemic antibiotics required 4
• Breakthrough UTIs occur in 26-42% of patients despite prophylaxis 2, 1; reassess diagnosis and consider alternative strategies
• Resistance development is uncommon (4%) but monitor culture patterns 2
• Intraoperative single-dose irrigation shows limited benefit and may paradoxically increase BK viremia risk (5.9% vs 2.5%, p=0.02) 6

Patient Selection

Ideal candidates:

• Neurogenic bladder with rUTIs despite oral prophylaxis
• Complex urological conditions (myelomeningocele, bladder augmentation, renal transplant)
• Patients performing CIC with ≥2 UTIs per year
• Multidrug-resistant organisms precluding oral alternatives 2

Patient-reported outcomes:

• Median ease-of-use: 4/5 1
• Likelihood to recommend: 5/5 1